Advertisement

Treatment Outcome Measures for Spasmodic Dysphonia: A Systematic Review

      ABSTRACT

      Purpose

      This systematic review aims to identify instruments used to evaluate treatment outcomes for people with spasmodic dysphonia.

      Methods

      Electronic database (PubMed, Cochrane Library, Embase, and CINAHL) searches and hand-searching identified studies that evaluated treatment approaches for spasmodic dysphonia which included pre and post outcome data.

      Results

      A total of 4714 articles were retrieved from searching databases; 1165 were duplicates. Titles and abstracts of 3549 were screened, with 171 being selected for full-text review. During full-text review, 101 articles were deemed suitable for inclusion. An additional 24 articles were identified as suitable for inclusion through hand-searching of reference lists. Data was extracted from 125 studies, identifying 220 outcome measures. As per the World Health Organization's International Classification of Functioning (ICF), the majority measured body functions (n = 212, 96%). Outcomes that explored communication and participation in everyday life and attitudes towards communication (ie, activity and participation domains) were infrequent (n = 8; 4%). Quality of life, a paradigm outside of the scope of the ICF, was also captured by four outcome measures. No instruments evaluating communication partners’ perspectives were identified.

      Conclusions

      Currently there is no unified approach to the measurement of outcomes in SD treatment research. Development and implementation of a core outcome set is recommended to facilitate improved understanding of the efficacy of current and new treatment options.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Voice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barkmeier J.M.
        • Case J.L.
        • Ludlow C.L
        Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
        J Comm Dis. 2001; 34: 21-37
        • Blitzer A.
        • Brin M.F.
        • Stewart C
        Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
        Laryngoscope. 1998; 108: 1435-1441
        • Rubin A.D.
        • Wodchis W.P.
        • Spak C.
        • et al.
        Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
        Arch Otolaryngol Head Neck Surg. 2004; 130: 415-420
      1. National Spasmodic Dysphonia Association, Spasmodic dysphonia. Available from: http://www.dysphonia.org/spasmodic-dysphonia.php 2016. Accessed March 16 2017

        • Schweinfurth J.M.
        • Billante M.
        • Courey M.S
        Risk factors and demographics in patients with spasmodic dysphonia.
        Laryngoscope. 2002; 112: 220-223
        • Izdebski K.
        • Dedo H.H.
        • Boles L
        Spastic dysphonia: a patient profile of 200 cases.
        Am J Otolaryngol. 1984; 5: 7-14
        • Baylor C.R.
        • Yorkston K.M.
        • Eadie T.L
        The consequences of spasmodic dysphonia on communication-related quality of life: a qualitative study of the insider's experiences.
        J Comm Dos. 2005; 38: 395-419
        • Smith E.
        • Taylor M.
        • Mendoza M.
        • et al.
        Spasmodic dysphonia and vocal fold paralysis: outcomes of voice problems on work-related functioning.
        J Voice. 1998; 12: 223-232
        • Aronson A.E.
        • Hartmann D.E
        Adductor spastic dysphonia as a sign of essential (voice tremor).
        J Speech Hear Disord. 1981; 46: 52-58
        • Blitzer A.
        • Lovelace R.E.
        • Brin M.F.
        • et al.
        Electromyographic findings in focal laryngeal dystonia (dysphonia).
        Ann Otol Rhinol Laryngol. 1985; 94: 591-594
        • Kirke D.N.
        • Frucht S.J.
        • Simonyan K.
        Alcohol responsiveness in laryngeal dystonia: a survey study.
        J Neurol. 2015; 262: 1548-1556
        • Novakovic D.
        • Water H.H
        • D'Elia J.B.
        • et al.
        Botulinum toxin treatment of adductor spasmodic dysphonia: Longitudinal functional outcomes.
        Laryngoscope. 2011; 121: 606-612
        • Roy N.
        • Barkmeier-Kraemer J.
        • Eadie T.
        • et al.
        Evidence-based clinical voice assessment: a systematic review.
        Am J Speech Lang Pathol. 2013; 22: 212-216
        • Dejonckere P.H.
        • Bradley P.
        • Clemente P.
        • et al.
        A basic protocol for functional assessment of voice pathology, especially for investigating the efficacy of (phonosurgical) treatments and evaluating new assessment techniques: guideline elaborated by the Committee of Phoniatrics of the.
        European Laryngological SOCIETY (ELS), Eur Arch Otorhinolaryngol. 2001; 258: 77-82
        • Prinsen C.A.C.
        • Vohra S.
        • Rose M.R.
        • et al.
        Core outcome measures in effectiveness trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set.
        Trials. 2014; 15https://doi.org/10.1186/1745-6215-15-247
        • Williamson P.R.
        • Altman D.G.
        • Blazeby J.M.
        • et al.
        Developing core outcome sets for clinical trials: Issues to consider.
        Trials. 2012; 13: 132https://doi.org/10.1186/1745-6215-13-132
        • Prinsen C.A.C
        • Vohra Z.
        • Rose M.R.
        • et al.
        How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline.
        Trials. 2016; 17: 1-10https://doi.org/10.1186/s13063-016-1555-2
        • Moher D.
        • Liberati A.
        • Tatzlaff J
        • et al.
        Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
        J Clin Epidemiol. 2009; 62: 1006-1012
        • Abdoerrachman H
        Perceptual and acoustic assessments on spasmodic dysphonia: pre and post-botulinum toxin injection.
        Med J Indones. 1997; 6: 158-163
        • Adams S.G.
        • Durkin L.C.
        • Irish J.C.
        • et al.
        Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
        Laryngoscope. 1996; 106: 296-300
        • Adams S.G.
        • Hunt E.J.
        • Charles D.A.
        • et al.
        Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
        J Otolaryngol. 1993; 22: 171-175
        • Adams S.G.
        • Hunt E.J.
        • Irish J.C.
        • et al.
        Comparison on botulinum toxin injection procedures in adductor spasmodic dysphonia.
        J Otolaryngol. 1995; 24: 345-351
        • Adler C.H
        • Bansberg S.F.
        • Krein-Jones K.
        • et al.
        Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
        Mov Disord. 2004; 19: 1075-1079
        • Ali S.O.
        • Schulz G.M.
        • Hosey L.A.
        • et al.
        Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: A H2150 PET study.
        J Speech Lang Hear Res. 2006; 49: 1127-1146
        • Allegretto M.
        • Morrison M.
        • Rammage L.
        • et al.
        Selective denervation: reinnervation for the control of adductor spasmodic dysphonia.
        J Otolaryngol. 2003; 32: 185-189
        • Anari S.
        • Carding P.N.
        • Hawthorne M.R.
        • et al.
        Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
        Laryngoscope. 2007; 117: 1888-1892
        • Aronson A.E.
        • DeSanto L.W.
        Adductor spastic dysphonia: 1½ years after recurrent laryngeal nerve resection.
        Ann Otol. 1981; 90: 2-6
        • Aronson A.E.
        • DeSanto L.W.
        Adductor spastic dysphonia: Three years after recurrent laryngeal nerve resection.
        Laryngoscope. 1983; 93: 1-8
        • Aronson A.E.
        • McCaffrey T.V.
        • Litchy W.J.
        • et al.
        Botulinum toxin injection for adductor spastic dysphonia: Patient self-ratings of voice and phonatory effort after three successive injections.
        Laryngosope. 1993; 103: 683-692
        • Bender B.K.
        • Cannito M.P.
        • Murry T.
        • et al.
        Speech intelligibility in severe adductor spasmodic dysphonia.
        J Speech Lang Hear Res. 2004; 47: 21-32
        • Benninger M.S.
        • Gardner G.
        • Grywalski C.
        Outcome of botulinum toxin treatment for patients with spasmodic dysphonia.
        Arch Otolaryngol Head Neck Surg. 2001; 127: 1083-1085
        • Berke G.S.
        • Blackwekk K.E.
        • Gerratt B.R.
        • et al.
        Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 1999; 108: 227-231
        • Bielamowicz S.
        • Squire S.
        • Bidus K.
        • et al.
        Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 2001; 100: 406-412
        • Bielamowicz S.
        • Ludlow C.L.
        Effects of botulinum toxin of pathophysiological in spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 2000; 109: 194-203
        • Blitzer A.
        • Brin M.F.
        Laryngeal dystonia: a series with botulinum toxin therapy.
        Ann Otol Rhinol Laryngol. 1991; 100: 85-89
        • Blitzer A.
        • Brin M.F.
        Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin.
        J Voice. 1992; 6: 365-369
        • Blitzer A.
        • Brin M.F.
        • Stewart C.
        • et al.
        Abductor laryngeal dystonia: a series treated with botulinum toxin.
        Laryngoscope. 1992; 102: 163-167
        • Boseley M.E.
        • Gherson S.
        • Hartnick C.J.
        Spasmodic dysphonia in an adolescent patient with an autoimmune neurologic disorder.
        Am J Otolaryngol Head Neck Med Surg. 2007; 28: 140-142
        • Brin M.F.
        • Blitzer A.
        • Fahn S.
        • et al.
        Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of botulinum toxin (Botox).
        Mov Disord. 1989; 4: 287-296
        • Brin M.F.
        • Blitzer A.
        • Stewart C.
        Laryngeal dystonia (spasmodic dysphonia): Observations of 901 patients and treatment with botulinum toxin.
        Dystonia 3Adv Neurol. 1998; 78: 237-252
        • Cannito M.P.
        • Buder E.H.
        • Chorna L.B.
        Spectral amplitude measures of adductor spasmodic dysphonic speech.
        J Voice. 2005; 19: 391-410
        • Cannito M.P.
        • Doiuchi M.
        • Murry T.
        • et al.
        Perceptual structure of adductor spasmodic dysphonia and its acoustic correlates.
        J Voice. 2012; 26 (818.e5-e13)
        • Cannito M.P.
        • Murry T.
        • Woodson G.E.
        Attitudes toward communication in adductor spasmodic dysphonia before and after botulinum toxin injection.
        J Med Speech Lang Pathol. 1994; 2: 125-133
        • Cannito M.P.
        • Woodson G.E.
        • Murry T.
        • et al.
        Perceptual analyses of spasmodic dysphonia before and after treatment.
        Arch Otolaryngol Head Neck Surg. 2004; 130: 1393-1399
        • Cantarella G.
        • Berlusconi A.
        • Maraschi B.
        • et al.
        Botulinum toxin injection and airflow stability in spasmodic dysphonia.
        Otolaryngol Head Neck Surg. 2006; 134: 419-423
        • Chan S.W.
        • Baxter M.
        • Oates J.
        • et al.
        Long-term results of Type II thyroplasty for adductor spasmodic dysphonia.
        Laryngoscope. 2004; 114: 1604-1608
        • Chhetri D.K.
        • Berke G.S.
        Treatment of adductor spasmodic dysphonia with selective laryngeal adductor denervation and reinnervation surgery.
        Otolaryngol Clin North Am. 2006; 39: 101-109
        • Courey M.S.
        • Garrett C.G.
        • Billante C.R.
        • et al.
        Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
        Ann Otol Rhinol Laryngol. 2000; 109: 819-822
        • Crevier-Buchman L.
        • Laccourreye O.
        • Papon J-F.
        • et al.
        Adductor spasmodic dysphonia: Case reports with acoustic analysis following botulinum toxin injection and acupuncture.
        J Voice. 1997; 11: 232-237
        • Damrose J.F.
        • Goldman S.N.
        • Groessl E.J.
        • et al.
        The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
        J Voice. 2004; 18: 415-422
        • Dedo H.H.
        • Behlau M.S
        Recurrent laryngeal nerve section for spastic dysphonia: 5- to 14-year preliminary results in the first 300 patients.
        Ann Otol Rhinol Laryngol. 1991; 100: 274-279
        • Dedo H.H.
        • Izdebski K.
        Evaluation and treatment of recurrent spasticity after recurrent laryngeal nerve section: a preliminary report.
        Ann Otol Rhinol Laryngol. 1984; 93: 343-345
        • Dejonckere P.H.
        • Neumann K.J.
        • Moreman M.B.J.
        • et al.
        Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with botulinum toxin.
        Eur Arch Otorhinolaryngol. 2012; 269: 1195-1203
        • Dromey C.
        • Reese A.
        • Howey S.
        Lip kinematics in spasmodic dysphonia before and after treatment with botulinum toxin.
        J Med Speech Lang Pathol. 2007; 15: 263-277
        • Epstein R.
        • Stygall J.
        • Newman S.
        Anxiety associated with botox injections for adductor spasmodic dysphonia.
        Logopedica Phoniatrics Vocology. 1996; 21: 3-4
        • Epstein R.
        • Stygall J.
        • Newman S.
        The short-term impact of botox injections on speech disability in adductor spasmodic dysphonia.
        Disabil Rehabil. 1997; 19: 20-25
        • Esposito M.
        • Dubbioso R.
        • Apisa P.
        • et al.
        Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectography during treatment with botulinum toxin.
        Neurol Sci. 2015; 36: 1679-1682
        • Finnegan E.M.
        • Luschei E.S.
        • Gordon J.D.
        • et al.
        Increased stability of airflow following botulinum toxin injection.
        Laryngoscope. 1999; 109: 1300-1306
        • Fisher K.V.
        • Scherer R.C.
        • Guo C.G.
        • et al.
        Longitudinal phonatory characteristics after botulinum toxin type A injection.
        J Speech Hear Res. 1996; 39: 968-980
        • Fisher K.V.
        • Scherer R.C.
        • Swank P.R.
        • et al.
        Electroglottographic tracking of phonatory response to botox.
        J Voice. 1999; 13: 203-218
        • Ford C.N.
        • Bless D.M.
        • Lowery J.D.
        Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia.
        Otolaryngol Head Neck Surg. 1990; 103: 752-758
        • Ford C.N.
        • Bless D.M.
        • Patel N.Y.
        Botulinum toxin treatment of spasmodic dysphonia: Techniques, indications, efficacy.
        J Voice. 1992; 6: 370-376
        • Fritzell B.
        • Feuer E.
        • Haglund S.
        • et al.
        Experiences with recurrent laryngeal section for spastic dysphonia.
        Folia Phoniat. 1982; 34: 160-167
        • Fritzell B.
        • Hammarberg B
        • Schiratzki H.
        • et al.
        Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia.
        J Voice. 1993; 7: 172-178
        • Gandhi S.
        • Remacle M.
        • Mishra P.
        • et al.
        Vocal outcome after endoscopic thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia.
        Eur Arch Otorhinolaryngol. 2014; 271: 3249-3254
        • Geneid A.
        • Lindestad P-A.
        • Granqvist S.
        • et al.
        Long-term follow-up of patients with spasmodic dysphonia and improved voice despite discontinuation of treatment.
        Folia Phoniatrica et Logopaedica. 2016; 68: 144-151
        • Green D.C.
        • Berke G.S.
        • Ward P.H.
        • et al.
        Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 1992; 101: 883-887
        • Hartmann V.
        • Hartmann C.J.
        • Hefter H.
        • et al.
        Correlation of self-assessment with expert rating and acoustic analysis for spasmodic dysphonia treatment with botulinum neurotoxin A.
        Basal Ganglia. 2013; 3: 165-169
        • Haslinger B.
        • Erhard P.
        • Dresel C.
        • et al.
        Silent event-related” fMRI reveals reduced sensorimotor activation in laryngeal dystonia.
        Neurology. 2005; 65: 1562-1569
        • Henschen T.L.
        • Burton N.G
        Treatment of spastic dysphonia by EMG biofeedback.
        Biofeedback Self Regul. 1978; 3: 91-96
        • Hogikyan N.D.
        • Wodchis W.P.
        • Spak C.
        • et al.
        Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
        J Voice. 2001; 15: 576-586
        • Hussain A.
        • Shakeel M.
        Selective lateral laser thyroarytenoid myotomy for adductor spasmodic dysphonia.
        J Laryngol Otol. 1984; 124: 886-891
        • Isshiki N.
        • Tsuji D.H.
        • Yamamoto Y.
        • et al.
        Midline lateralization thyroplasty for adductor spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 2000; 109: 187-193
        • Izdebski K.
        • Dedo H.H.
        • Shipp T.
        • et al.
        Postoperative and follow-up studies of spastic dysphonia patients treated by recurrent laryngeal nerve section.
        Otolaryngol Head Neck Surg. 1981; 89: 96-101
        • Kaszas Z.
        • Lichtenberger G.
        • Meszaros K.
        • et al.
        Spasmodic dysphonia combined with insufficient glottis closure by phonation.
        Eur Arch Otorhinolaryngol. 2003; 260: 418-420
        • Kendall K.A.
        • Leonard R.J.
        Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
        J Voice. 2011; 25: 114-119
        • Kim H.S.
        • Choi H-S
        • Kim J-Y.
        • et al.
        Radiofrequency thyroarytenoid myothermy for treatment of adductor spasmodic dysphonia: how we do it.
        Clinical Otolaryngology. 2008; 33: 607-628
        • Kim J.W.
        • Park J.H.
        • Park K.N.
        • et al.
        Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: A prospective comparative study.
        Scientific World Journal. 2014; 327928
        • Klein A.M.
        • Stong B.C.
        • Wise J.
        • et al.
        III. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
        Otolaryngol Head Neck Surg. 2008; 139: 421-423
        • Koufman J.A.
        Preliminary report: management of abductor spasmodic dysphonia by endoscopic partial posterior cricoarytenoid (PCA) myectomy.
        Phonoscope. 1999; 2: 159-164
        • Koufman J.A.
        • Rees C.J.
        • Halum S.L.
        • et al.
        Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report.
        Ann Otol Rhinol Laryngol. 2006; 115: 97-102
        • Langeveld T.P.M.
        • Drost H.A.
        • Baatenburg de Jong R.J.
        Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 1998; 107: 280-284
        • Langeveld T.P.M.
        • Luteijn F.
        • van Rossum M.
        • et al.
        Adductor spasmodic dysphonia and botulinum toxin treatment: The effect on well-being.
        Ann Otol Rhinol Laryngol. 2001; 110: 941-945
        • Langeveld T.P.M
        • van Rossum M.
        • Houtman E.H.
        • et al.
        Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
        Ann Otol Rhinol Laryngol. 2001; 110: 627-634
        • Liu T.C
        • Irish J.C.
        • Adams S.G.
        • et al.
        Prospective study of patients’ subjective responses to botulinum toxin injection for spasmodic dysphonia.
        J Otolaryngol. 1996; 25: 66-74
        • Liu C-Y.
        • Yu J-M.
        • Wang N-M.
        • et al.
        Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia.
        Gen Hosp Psychiatry. 1998; 20: 255-259
        • Ludlow C.L.
        • Naunton R.F.
        • Fujita M.
        • et al.
        Spasmodic dysphonia: Botulinum toxin injection after recurrent nerve surgery.
        Otolaryngol Head Neck Surg. 1990; 102: 122-131
        • Ludlow C.L.
        • Naunton R.F.
        • Sedory S.E.
        • et al.
        Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
        Neurology. 1988; 38: 1220-1225
        • Ludlow C.L.
        • Naunton R.F.
        • Terada S.
        • et al.
        Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection.
        Otolaryngol Head Neck Surg. 1991; 104: 849-855
        • Lundy D.S.
        • Lu F.L.
        • Casiano R.R.
        • et al.
        The effect of patient factors on response outcomes to botox treatment of spasmodic dysphonia.
        J Voice. 1998; 12: 460-466
        • Maronian N.C.
        • Waugh P.F.
        • Robinson L.
        • et al.
        Tremor laryngeal dystonia: Treatment of the lateral cricoarytenoid muscle.
        Ann Otol Rhinol Laryngol. 2004; 113: 349-355
        • Mehta R.P.
        • Golman S.N.
        • Orloff L.A.
        Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes.
        Arch Otolaryngol Head Neck Surg. 2001; 127: 393-399
        • Meyers I.
        • Anderson D.
        A stuttering therapy programme with spastic dysphonia – a single case study.
        S Afr J Commun Disord. 1985; 32: 31-36
        • Miller R.H.
        • Woodson G.E.
        • Jankovic J.
        Botulinum toxin injection of the vocal fold for spasmodic dysphonia.
        Arch Otolaryngol Head Neck Surg. 1987; 113: 603-605
        • Morzaria S.
        • Damrose E.J.
        The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
        J Laryngol Otol. 2011; 125: 714-718
        • Morzaria S.
        • Damrose E.J.
        A comparison of the VHI, VHI-10, V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
        J Voice. 2012; 26: 378-380
        • Murry T.
        • Cannito M.P.
        • Woodson G.E.
        Spasmodic dysphonia: Emotional status and botulinum toxin treatment.
        Arch Otolaryngol Head Neck Surg. 1994; 120: 310-316
        • Murry T.
        • Woodson G.E.
        Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
        J Voice. 1995; 9: 460-465
        • Nakamura K.
        • Muta H.
        • Watanabe Y.
        • et al.
        Surgical treatment for adductor spasmodic dysphonia – efficacy of bilateral thyroarytenoid myectomy under microlaryngoscopy.
        Acta Oto-Laryngologica. 2008; 128: 1348-1353
        • Nomoto M.
        • Tokashiki R.
        • Hiramatsu H.
        • et al.
        The comparison of thyroarytenoid muscle myectomy and type II thyroplasty for spasmodic dysphonia.
        J Voice. 2015; 29: 501-506
        • Paniello R.C.
        • Barlow J.
        • Serna J.S.
        Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
        Laryngoscope. 2008; 118: 564-568
        • Paniello R.C.
        • Edgar J.D.
        • Perlmutter J.S.
        Vocal exercises versus voice rest following botulinum toxin injections: a randomized crossover trial.
        Ann Otol Rhinol Laryngol. 2009; 118: 759-763
        • Remacle M.
        • Plouin-Gaudon I.
        • Lawson G.
        • et al.
        Bipolar radiofrequency-induced thermotherapy (rfitt) for the treatment of spasmodic dysphonia. A report of three cases.
        Eur Arch Otorhinolaryngol. 2005; 262: 871-874
        • Rhew K.
        • Fielder D.A.
        • Ludlow C.L.
        Technique for injection of botulinum toxin through the flexible nasolaryngoscope.
        Otolaryngol Head Neck Surg. 1994; 111: 787-794
        • Rojas G.V.
        • Ricz H.
        • Tumas V.
        • et al.
        Vocal parameters and self-perception in individuals with adductor spasmodic dysphonia.
        J Voice. 2017; 31 (391.e7-e18)
        • Rontal M.
        • Rontal E.
        • Rolnick M.
        • et al.
        A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
        Laryngoscope. 1991; 101: 911-914
        • Rubin A.D.
        • Wodchis W.P.
        • Spak C.
        • et al.
        Longitudinal effects of botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: Part II.
        Arch Otolaryngol Head Neck Surg. 2004; 130: 415-420
        • Rumbach A.F.
        • Blitzer A.
        • Frucht S.J.
        • et al.
        An open-label study of sodium oxybate in spasmodic dysphonia.
        Laryngoscope. 2017; 127: 1402-1407
        • Salvatore A.P.
        • Cannito M
        • Biswas A.
        • et al.
        Longitudinal study of temporal speech alterations in an individual with adductor spasmodic dysphonia treated with botulinum toxin.
        J Med Speech Lang Pathol. 2007; 15: 67-82
        • Sanuki T.
        • Isshiki N.
        Overall evaluation of effectiveness of type II thyroplasty for adductor spasmodic dysphonia.
        Laryngoscope. 2007; 117: 2255-2259
        • Sanuki T.
        • Yumoto E.
        • Kodama N.
        • et al.
        Long-term Voice Handicap Index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.
        Auris Nasus Larynx. 2014; 41: 285-289
        • Sanuki T.
        • Yumoto E.
        • Minoda R.
        • et al.
        Effects of type II thyroplasty on adductor spasmodic dysphonia.
        Otolaryngol Head Neck Surg. 2010; 142: 540-546
        • Sapienza C.M.
        • Cannito M.P.
        • Murry T.
        • et al.
        Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection.
        J Speech Lang Hear Res. 2002; 45: 830-843
        • Schonweiler R.
        • Wohlfarth K.
        • Dengler R.
        • et al.
        Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.
        Laryngoscope. 1998; 108: 55-63
        • Shaw G.Y.
        • Sechtem P.R.
        • Rideout B.
        Posterior cricoarytenoid myoplasty with medialization thyroplasty in the management of refractory abductor spasmodic dysphonia.
        Ann Otol Rhinol Laryngol. 2003; 112: 303-306
        • Silverman E.P.
        • Garvan C.
        • Shrivastav R.
        • et al.
        Combined modality treatment of adductor spasmodic dysphonia.
        J Voice. 2012; 26: 77-86
        • Simonyan K.
        • Frucht S.J.
        Long-term effect of sodium oxybate (Xyrem®) in spasmodic dysphonia with vocal tremor.
        Tremor Other Hyperkinet Mov. 2013; 3: 3
        • Srirompotong S.
        • Saeseow P.
        • Taweesaengsuksakul R.
        • et al.
        Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
        J Med Assoc Thai. 2006; 89: 2077-2080
        • Su C-Y.
        • Chuang H-C.
        • Tsai S-S.
        • et al.
        Transoral approach to laser thyroarytenoid myoneurectomy for treatment of adductor spasmodic dysphonia: short-term results.
        Ann Otol Rhinol Laryngol. 2007; 116: 11-18
        • Su C-Y.
        • Lai C-C.
        • Wu P-Y.
        • et al.
        Transoral laser ventricular fold resection and thyroarytenoid myoneurectomy for adductor spasmodic dysphonia: long-term outcome.
        Laryngoscope. 2010; 120: 313-318
        • Sulica L.
        • Blitzer A.
        • Brin M.F.
        • et al.
        Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
        Ann Otol Rhinol Laryngol. 2003; 112: 499-505
        • Tisch S.H.D
        • Brake H.M.
        • Law M.
        • et al.
        Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients- An Australian experience.
        J Clin Neurosci. 2003; 10: 434-438
        • Truong D.D.
        • Rontal M.
        • Rolnick M.
        • et al.
        Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
        Laryngoscope. 1991; 101: 630-634
        • Tsuji D.H.
        • Chrispim F.S.
        • Imamura R.
        • et al.
        Impact in vocal quality in partial myectomy and neurectomy endoscopic of thyroarytenoid muscle in patients with adductor spasmodic dysphonia.
        Rev Bras Otorrinolaringol. 2006; 72: 261-266
        • Tsuji D.H.
        • Takahashi M.T.
        • Imamura R.
        • et al.
        Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
        J Voice. 2012; 26 (666.e7-e12)
        • Tsunoda K.
        • Amagai N.
        • Kondou K.
        • et al.
        Autologous replacement of the vocal fold: a new surgical approach for adduction-type spasmodic dysphonia.
        J Laryngol Otol. 2005; 119: 222-225
        • Wang N.M
        • Lu C-S.
        Botulinum toxin management of adductor spasmodic dysphonia with vocal tremors.
        J Med Speech Lang Path. 2004; 12: 1-8
        • Whurr R.
        • Lorch M.
        • Fontana H.
        • et al.
        The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
        J Neurol Neurosurg Psychiatry. 1993; 56: 526-530
        • Whurr R.
        • Lorch M.
        • Lindsay M.
        • et al.
        Psychological function in spasmodic dysphonia before and after treatment with botulinum toxin.
        J Med Speech Lang Path. 1998; 6: 81-91
        • Wilson F.B.
        • Oldring D.J.
        • Mueller K.
        Recurrent laryngeal nerve dissection: a case report involving return of spastic dysphonia after initial surgery.
        J Speech Hear Disord. 1980; 45: 112-118
        • Wingate J.M.
        • Hoffman Ruddy B.
        • Lundy D.S.
        • et al.
        Voice Handicap Index results for older patients with adductor spasmodic dysphonia.
        J Voice. 2005; 19: 124-131
        • Witsell D.L.
        • Weissler M.C.
        • Donovan K.
        • et al.
        Measurement of laryngeal resistance in the evaluation of botulinum toxin injection for treatment of focal laryngeal dystonia.
        Laryngoscope. 1994; 104: 8-11
        • Wong D.L.H.
        • Irish J.
        • Adams S.G.
        • et al.
        Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia.
        J Otolaryngol. 1995; 24: 64-68
        • Woo P.
        • Colton R.
        • Casper J.
        • et al.
        Analysis of spasmodic dysphonia by aerodynamic and laryngostroboscopic measurements.
        J Voice. 1992; 6: 344-351
        • Woodson G.E.
        • Zwirner P.
        • Murry T.
        • et al.
        Use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia.
        J Voice. 1991; 5: 85-91
        • Young N.
        • Blitzer A
        Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
        Laryngoscope. 2007; 117: 2082-2084
        • Zwirner P.
        • Murry T.
        • Swenson M.
        • et al.
        Acoustic changes in spasmodic dysphonia after botulinum toxin injection.
        J Voice. 1991; 5: 78-84
        • Zwirner P.
        • Murry T.
        • Swenson M.
        • et al.
        Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
        Laryngoscope. 1992; 102: 400-406
        • Zwirner P.
        • Murry T.
        • Woodson G.E
        Perceptual-acoustic relationships in spasmodic dysphonia.
        J Voice. 1993; 7: 165-171
        • Zwirner P.
        • Murry T.
        • Woodson G.E
        A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.
        Eur Arch Otorhinolaryngol. 1993; 250: 271-276
        • Zwirner P.
        • Murry T.
        • Woodson G.E
        Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia.
        Eur Arch Otorhinolaryngol. 1997; 254: 391-395
        • World Health Organization
        World Health Organization: International Classification of Functioning.
        Disability and Health (ICF), 2001 (Available from)
        www.who.int
        Date accessed: March 16, 2017
        • Beck A.
        • Ward C.
        • Mendelson M.
        • et al.
        An inventory for measuring depression.
        Arch Gen Psychiatr. 1961; 4: 561-571
        • Wilson D
        Voice problems of children.
        third ed. Williams and Wilkins, Baltimore1987
        • Posner K.
        • Brow G.K.
        • Stanlet B.
        • et al.
        The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multiside studies with adolescents and adults.
        Am J Psychiatr. 2011; 168: 1266-1277
        • Crown S.
        • Crisp A
        A short clinical diagnostic self-rating scale for psychoneurotic patients.
        Br J Psychiatry. 1966; 112: 917-923
        • Johns M.W
        A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
        Sleep. 1991; 14: 540-545
        • Erickson R.L
        Assessing communication attitudes among stutterers.
        J Speech Hear Res. 1969; 12: 711-724
        • Bach K.K.
        • Belafsky P.C.
        • Wasylik K.
        • et al.
        Validity and reliability of the glottal function index.
        Arch Otolaryngol Head Neck Surg. 2005; 131: 961-964
        • Hyland M.E.
        • Finnis S.
        • Irvine S.H
        A scale for assessing quality of life in adult asthma sufferers.
        J Psychosom Res. 1991; 35: 99-110
        • Hamilton M
        The assessment of anxiety state by rating.
        Br J Med Psyc. 1959; 32: 50-55
        • Hamilton M
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Derogatis L.R.
        • Lipman R.S.
        • Rickels K.
        • et al.
        The Hopkins symptom checklist (HSCL): a self-report symptom inventory.
        Behav Sci. 1974; 19: 1-15
        • Nasereddine Z.S.
        • Phillips N.A.
        • Bedirian V.
        • et al.
        The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment.
        J Am Geriatr Soc. 2005; 53: 695-699
        • Folstein M.F.
        • Folstein S.E.
        • McHugh P.R
        Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • McNair D.M.
        • Lorr M
        An analysis of mood in neurotics.
        J Abnorm Soc Psychol. 1964; 69: 620-627
        • Cohen S.
        • Kamarck T.
        • Mermelstein R
        A global measure of perceived stress.
        J Health Soc Behav. 1983; 24: 385-396
        • Zung W.W.K
        The measurement of depression.
        Lakeside Laboratories, Milwaukee, Wis1965
        • Ware J.E.
        • Snow K.K.
        • Kosuski M.
        • et al.
        SF-36 Health Survey manual and interpretation guide.
        The Health Institute, Boston1993
        • Cannito M.P
        Emotional considerations in spasmodic dysphonia: psychometric quantification.
        J Comm Dis. 1991; 24: 313-329
        • Spielberger G.D.
        • Gorusch R.L.
        • Lushene R.
        • et al.
        Manual for the State-Trait Anxiety Inventory (Form Y Self-Evaluation Questionnaire).
        Consulting Psychologists Press, Palo Alto1983
        • Derogatis L.R.
        • Lipman R.S.
        • Covi L
        SCL-90: An outpatient psychiatric rating scale – preliminary report.
        Psychopharmacol Bull. 1973; 9: 13-28
        • Ma E.P-M.
        • Yiu E.M-L
        Voice activity and participation profile: assessing the impact of voice disorders on daily activities.
        J Speech Lang Hear Res. 2001; 44: 511-524
        • Jacobson B.H.
        • Johnson A.
        • Grywalski C.
        • et al.
        The Voice Handicap Index (VHI): development and validation.
        Am J Speech Lang Pathol. 1997; 6: 66-70
        • Rosen C.A.
        • Lee A.S.
        • Osborne J.
        • et al.
        Development and validation of the voice handicap index-10.
        Laryngoscope. 2004; 114: 1549-1556
        • Hogikyan N.D.
        • Sethuraman G
        Validation of an instrument to measure voice-related quality of life (VRQOL).
        J Voice. 1999; 13: 557-569
        • Dykstra A.D.
        • Hakel M.E.
        • Adams S.G
        Application of the ICF in reduced speech intelligibility in dysarthria.
        Semin Speech Lang. 2007; 28: 301-311
        • Stewart C.F.
        • Allen E.L.
        • Tureen P.
        • et al.
        Adductor spasmodic dysphonia: standard evaluation of symptoms and severity.
        J Voice. 1997; 11: 95-103
        • Hirano M
        Clinical examination of voice.
        Springer-Verlag, New York1981
        • Moerman M.
        • Martens J.P.
        • Crevier-Buchman L.
        • et al.
        The INFVo perceptual rating scale for substitution voicing: development and reliability.
        Eur Arch Otorhinolaryngol. 2006; 263: 435-439
        • Ludlow C.L.
        • Adler C.H.
        • Berke G.S
        Research priorities in spasmodic dysphonia.
        Otolaryngol Head Neck Surg. 2008; 139: 495-505
        • Siemons-Luhring D.I.
        • Moerman M.
        • Martens J-P.
        • et al.
        Spasmodic dysphonia, perceptual and acoustic analysis: presenting new diagnostic tools.
        Eur Arch Otorhinolaryngol. 2009; 266: 1915-1922
        • Aronson A.E
        Clinical voice disorders: an interdisciplinary approach.
        Thieme Inc, New York1990
      2. PCORI Methodology Committee. The PCORI (Patient-Centred Outcomes Research Institute) methodology report. 2013. Available from:www.pcori.org/research-we-support/research-methodology-standards. Accessed March 16 2017.

        • Boutsen F.
        • Cannito M.P.
        • Taylor M.
        • et al.
        Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
        J Speech Lang Hear Res. 2002; 45: 469-481
        • Edgar J.D.
        • Sapienza C.M.
        • Bidus K.
        • et al.
        Acoustic measures of symptoms in abductor spasmodic dysphonia.
        J Voice. 2001; 15: 362-372
        • Baylor C.R.
        • Yorkston K.M.
        • Eadie T.L.
        • et al.
        The psychosocial consequences of BOTOX Injections for spasmodic dysphonia: a qualitative study of patients’ experiences.
        J Voice. 2007; 21: 231-247
        • van Esch B.F.
        • Wegner I.
        • Stegeman I.
        • et al.
        Effect of botulinum toxin and surgery among spasmodic dysphonia patients: a systematic review. 156. Otolaryngol Head Neck Surg, 2017: 238-254
      3. Wallace S.J.. Improving research outcome measurement in aphasia: Development of a core outcome set. PhD Thesis, School of Health and Rehabilitation Sciences, The University of Queensland. https://doi.org/10.14264/uql.2017.61

        • Wallace S.J.
        • Worrall L.
        • Rose T.
        • et al.
        Which outcomes are most important to people with aphasia and their families? An international nominal group technique study framed within the ICF.
        Disability and Rehabilitation. 2016; 39: 1-16
        • Wallace S.J.
        • Worrall L.
        • Rose T.
        • et al.
        Which treatment outcomes are most important to aphasia clinicians and managers? An international e-Delphi consensus study.
        Aphasiology. 2017; 31: 643-673
        • Wallace S.J.
        • Worrall L.
        • Rose T.
        • et al.
        Core outcomes in aphasia treatment research: an e-Delphi consensus study of international aphasia researchers.
        Am J Speech Lang Pathol. 2016; 25: S729-S742
        • Wallace S
        • Worrall L
        • Le Dorze G
        • Brandenburg C
        • Foulkes J
        • Rose T
        Many ways of measuring: a scoping review of measurement instruments for use with people with aphasia.
        Aphasiology. 2020; : 1-66https://doi.org/10.1080/02687038.2020.1836318